REGENXBIO (RGNX) Revenue & Revenue Breakdown
REGENXBIO Revenue Highlights
Latest Revenue (Y)
$83.33M
Latest Revenue (Q)
$24.20M
Main Segment (Y)
License and Service
REGENXBIO Revenue by Period
REGENXBIO Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $83.33M | -7.66% |
| 2023-12-31 | $90.24M | -19.94% |
| 2022-12-31 | $112.72M | -76.03% |
| 2021-12-31 | $470.35M | 204.30% |
| 2020-12-31 | $154.57M | 338.70% |
| 2019-12-31 | $35.23M | -83.88% |
| 2018-12-31 | $218.50M | 2002.42% |
| 2017-12-31 | $10.39M | 126.48% |
| 2016-12-31 | $4.59M | -39.52% |
| 2015-12-31 | $7.59M | 23.99% |
| 2014-12-31 | $6.12M | 0.54% |
| 2013-12-31 | $6.09M | - |
REGENXBIO generated $83.33M in revenue during NA 2024, up -7.66% compared to the previous quarter, and up 236.51% compared to the same period a year ago.
REGENXBIO Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $24.20M | 8.53% |
| 2024-06-30 | $22.30M | 42.72% |
| 2024-03-31 | $15.62M | -29.67% |
| 2023-12-31 | $22.21M | -23.18% |
| 2023-09-30 | $28.91M | 44.74% |
| 2023-06-30 | $19.98M | 4.38% |
| 2023-03-31 | $19.14M | -38.94% |
| 2022-12-31 | $31.34M | 18.23% |
| 2022-09-30 | $26.51M | -18.80% |
| 2022-06-30 | $32.65M | 46.95% |
| 2022-03-31 | $22.22M | -94.43% |
| 2021-12-31 | $398.65M | 1195.47% |
| 2021-09-30 | $30.77M | 39.66% |
| 2021-06-30 | $22.04M | 16.69% |
| 2021-03-31 | $18.88M | -11.94% |
| 2020-12-31 | $21.45M | -78.32% |
| 2020-09-30 | $98.91M | 497.08% |
| 2020-06-30 | $16.57M | -6.11% |
| 2020-03-31 | $17.64M | 49.93% |
| 2019-12-31 | $11.77M | -19.95% |
| 2019-09-30 | $14.70M | 86.52% |
| 2019-06-30 | $7.88M | 791.52% |
| 2019-03-31 | $884.00K | -97.83% |
| 2018-12-31 | $40.78M | 668.51% |
| 2018-09-30 | $5.31M | -86.75% |
| 2018-06-30 | $40.03M | -69.76% |
| 2018-03-31 | $132.39M | 6389.75% |
| 2017-12-31 | $2.04M | 52.69% |
| 2017-09-30 | $1.34M | -79.64% |
| 2017-06-30 | $6.56M | 1342.20% |
| 2017-03-31 | $455.00K | -73.17% |
| 2016-12-31 | $1.70M | 1256.80% |
| 2016-09-30 | $125.00K | -94.74% |
| 2016-06-30 | $2.38M | 504.33% |
| 2016-03-31 | $393.00K | -91.16% |
| 2015-12-31 | $4.45M | 290.18% |
| 2015-09-30 | $1.14M | -16.36% |
| 2015-06-30 | $1.36M | 111.65% |
| 2015-03-31 | $644.00K | -43.90% |
| 2014-12-31 | $1.15M | 137.68% |
| 2014-09-30 | $483.00K | - |
REGENXBIO generated $24.20M in revenue during Q3 2024, up 8.53% compared to the previous quarter, and up 121.12% compared to the same period a year ago.
REGENXBIO Revenue Breakdown
REGENXBIO Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| License and Service | $83.33M | $90.24M | $112.72M | - | - |
| License And Service | - | - | - | $470.35M | $154.57M |
Latest
REGENXBIO's latest annual revenue breakdown by segment (product or service), as of Dec 24: License and Service (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and Service | $21.21M | $24.20M | $22.30M | $15.62M | $70.27M | $19.98M | $31.34M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| License And Service | - | - | - | - | - | - | $19.14M | $26.51M | $32.65M | $22.22M | $398.65M | $30.77M | $22.04M | $18.88M | - | - | - | - | - | - |
| Zolgensma Royalties | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $20.91M | $18.80M | $11.95M | $9.98M | $10.72M |
| License | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.50M | - | - |
| Achievement Of Sales Based Milestone For Zolgensma | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $80.00M | - | - | - |
Latest
REGENXBIO's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: License and Service (100.00%).
REGENXBIO Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MIRM | Mirum Pharmaceuticals | $336.89M | $77.88M |
| IMCR | Immunocore | $310.20M | $75.40M |
| DAWN | Day One Biopharmaceuticals | $131.16M | $20.07M |
| RGNX | REGENXBIO | $83.33M | $24.20M |
| GLUE | Monte Rosa Therapeutics | $75.62M | $4.70M |
| STOK | Stoke Therapeutics | $36.55M | $4.89M |
| QURE | uniQure | $27.12M | $2.29M |
| RNA | Avidity Biosciences | $10.90M | $2.04M |
| CRNX | Crinetics Pharmaceuticals | $1.04M | - |
| PTGX | Protagonist Therapeutics | - | $4.67M |
| ANTX | AN2 Therapeutics | - | - |
| FDMT | 4D Molecular Therapeutics | - | - |
| RCKT | Rocket Pharmaceuticals | - | - |
| RVMD | Revolution Medicines | - | - |
| REPL | Replimune Group | - | - |
| KZR | Kezar Life Sciences | - | - |
| PLRX | Pliant Therapeutics | - | - |
| PASG | Passage Bio | - | - |